Trial Information

Summary: Diarrhea Predominant Irritable Bowel Syndrome

A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Investigate the Safety and Efficacy of 2mg TID of Cilansetron Over 12 Weeks Followed by a 4-Week Rerandomized Treatment Period in Diarrhea-Predominant Irritable Bowel Syndrome.

You may be eligible to participate in this research trial if you:

• Are an established diarrhea-predominant irritable bowel syndrome subject
• Are at least 18 years old
• Do not have evidence of severe cardiovascular, respiratory or gastrointestinal disease
• Have not received treatment with any experimental drugs within four weeks prior to the study
• Do not have a history of alcohol or drug abuse
• Are not pregnant or breastfeeding

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:43:22 AM